Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
GW Pharmaceuticals
British biopharmaceutical company
Nothing else this week.
- FDA
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA approval boosts the Korean drug industry, driving market attention for companies like SamChunDang Pharm.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
Coverage
Newest first; wire copies grouped- Insider MonkeyJazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. O